miracle development group, inc.

4121 barker hill rd.
jamesville, new york 13078

NYS Entity Status
ACTIVE

NYS Filing Date
JUNE 18, 2013

NYS DOS ID#
4419273

County
ONONDAGA

Jurisdiction
NEW YORK

Registered Agent
NONE

NYS Entity Type
DOMESTIC BUSINESS CORPORATION

Name History
2013 - MIRACLE DEVELOPMENT GROUP, INC.









Buffer

submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • Around the Web

  • IAB Tech Lab Launches Blockchain Working Group
    Monday Sep 18, 2017

    GroupM, Kochava, MetaX, and Nyiax have become member companies in an IAB Tech Lab working group that launched Monday focused on blockchain and explore ways to use it in digital technology. ShailleySingh leads the group. The working group will initially design ways to educate the industry, set priorities for business use cases and develop standards and best practices. 

    Source: Media Post: Search Marketing Daily
  • AstraZeneca Shocker Reminds Investors Miracle Drugs Are No Remedy for Risk
    Thursday Jul 27, 2017

    Chasing exciting new developments in medicine can be a very expensive endeavor. Such is the takeaway from AstraZeneca’s announcement that a hotly anticipated clinical trial didn’t meet expectations.

    Source: The Wall Street Journal: Markets News
  • Solar Developers and Panel Makers Clash Over Tariff Request
    By DIANE CARDWELL - Tuesday Aug 15, 2017

    Troubled domestic manufacturers say cheap Chinese products have undercut their own, but industry groups are urging a trade panel to reject sanctions.

    Source: NYT > Home Page
  • Aimmune in Brisbane teams with Regeneron to find peanut allergy cure
    By Caroline Chen - Tuesday Oct 17, 2017

    Aimmune Therapeutics Inc. is teaming with Regeneron Pharmaceuticals Inc. in hopes of developing a cure for peanut allergies. Aimmune, based in Brisbane, specializes in food allergy treatments and has been developing a desensitizing therapy, AR101, to protect peanut allergy sufferers against reactions from accidental exposures. By combining AR101 with Regeneron’s inflammation-inhibiting drug Dupixent, the companies are seeking to increase protection enough so patients stop reacting to peanuts even after treatment ends. “What we’re learning is that the immune system does seem to be plastic, and with the right group, you can turn the disease back,” Aimmune’s chief executive officer, Stephen Dilly, said.

    Source: SFGATE.com: Business and Technology News
  • As Church Shifts, a Cardinal Welcomes Gays; They Embrace a ‘Miracle’
    By SHARON OTTERMAN - Tuesday Jun 13, 2017

    Cardinal Joseph W. Tobin of Newark, who welcomed gay worshipers at a recent Mass, is among a small but growing group of bishops changing how the Catholic Church relates to gay members.

    Source: NYT > Home Page
  • Restaurant Review: The Pool Strives to Deal With Its Famous Dining Room
    By PETE WELLS - Tuesday Oct 17, 2017

    Changes to the landmark interior of the former Four Seasons create challenges for the new restaurant from Major Food Group.

    Source: NYT > Home Page